Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00717522 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma
A Phase 2 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00717522 is a Phase 2 study that was terminated before completion, run by Celgene. The registered enrollment target is 7 participants.
The verdict
NCT00717522, a Phase 2 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety and efficacy of single agent CC-4047 (pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are refractory to prior anticancer therapy.
Interventions
- DRUG Pomalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-08-01 |
| Est. Completion | 2009-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00717522
The ClinicalTrials.gov registry entry for NCT00717522 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pomalidomide is the first listed.
NCT00717522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00717522 about?
NCT00717522 is a clinical study titled "Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma". The purpose of the study is to determine the safety and efficacy of single agent CC-4047 (pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are refractory to prior anticancer therapy.
What is the current status of trial NCT00717522?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2008-08-01. Estimated completion is 2009-01-01.
What interventions are being tested in trial NCT00717522?
The interventions under investigation include: Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT00717522?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.